Sathgen Therapeutics, a division of Godavari Biorefineries Limited, completed the Phase 1 clinical trial of MSP008-22, an anti-cancer drug, with Clinexel Life Sciences managing the clinical development program for global approvals.

Sathgen aims to develop MSP008-22 for difficult cancers, starting with Triple Negative Breast Cancer (TNBC) and prostate cancer. The lead molecule targets both bulk cancer cells and treatment-resistant populations, making it a promising candidate against aggressive cancers. In the first cohort, this NCE exhibited no adverse events.

“TNBC accounts for 15 percent of all breast cancer and 30 percent of breast cancer-related mortality. They are characterized by the lack of expression of the estrogen and progesterone receptors and HER2, making it difficult to treat with conventional hormone therapy. MSP008-22 will address the therapeutic discrepancy and need that exists for TNBC,” said Professor Sendurai Mani, Associate Director, Legorreta Cancer Center at Brown University and Scientific Co-Founder, Sathgen Therapeutics.

Dr Sangeeta Srivastava, Executive Director, Godavari Biorefineries Limited, and CSO, Sathgen Therapeutics commented -

“The clinical trial of MSP008-22 marks our first program in clinical development, a major milestone for us. This drug is our lead candidate for treating patients with TNBC and prostate cancer, and enhances standard-of-care chemotherapy.”  

Samir Somaiya, Chairman, and Managing Director, Godavari Biorefineries Limited, and Executive Co-Founder, Sathgen Therapeutics said -

“At Godavari Biorefineries, we value research as the core of our work, creating ongoing benefits for society. We focus on cancer drug discovery, as cancer is a devastating disease with limited effective treatments. The MSP008-22 clinical trial is a significant step forward in our mission to help patients with hard-to-treat cancers.”

Dr Deepa Arora, CEO, Clinexel, said -

“The completion of the first cohort of this study (NCT05478486) in patients with advanced solid tumors without any adverse events is encouraging. We are designing the clinical development program to expedite approvals for bringing a safe and effective oral therapy to address a therapeutic gap in managing TNBC and prostate cancer.”